Amazon deliveries could soon come with a new catch: the delivery driver's smart glasses will be snapping photos of anything they see while they're in use, including people and private property. Bloomberg reports that the glasses could take "several thousand captures in a single driver's typical shift," which Amazon plans to upload to its AI Wellspring platform. When asked if customers will be able to opt-out of this, Amazon's Viraj Chatterjee told Bloomberg, "We haven't thought about that." Chatterjee claimed Amazon's only using the data from the glasses to "enhance the delivery process," adding, "The intent has never been stuff like surve … Read the full story at The Verge.

Amazon&#8217;s delivery driver smart glasses will reportedly take photos &#8216;almost constantly&#8217;

Good morning. I have a gallon of apple cider I don&#x2019;t know what to do with. Please send any good recipes you have! The need-to-know this morning Moderna appointed Juan Andres as its new chief operating officer, a new executive role for the company as it prepares to expand into oncology. This is Andres&#x2019; second stint with Moderna. He previously served as its top executive in charge of manufacturing and quality control.&#xA0; Pierre Fabre Pharmaceuticals and Atara Biotherapeutics said their drug Ebvallo was refiled with the FDA. The companies are&#xA0;seeking approval to treat patients with an ultra-rare and fatal type of blood cancer that can develop in people who have received a stem cell or solid organ transplant. In May, the FDA agreed to review Ebvallo again after previously rejecting the drug.&#xA0; Beam alleges Chinese company stole its IP Beam Therapeutics has filed a lawsuit alleging one of its former&#xA0;scientists stole intellectual property and used it to co-found a Chinese company that recently made a deal with prominent VC firms. The allegations by Beam, based in Cambridge, comes amid escalating tensions between American biotechs and their Chinese counterparts. A growing number of U.S. investors and pharma companies are looking&#xA0;to China to license new drugs at lower costs, but American entrepreneurs and scientists have countered that Chinese biotechs are creating copycats of U.S drug candidates.Continue to STAT+ to read the full story&hellip;

STAT+: Three biotech updates, including accusations of theft and and a new lobbying leader

Google has launched a pilot program that pays publishers for their contributions to its AI-powered search features, according to a report from The Information. The pilot program reportedly includes around 100 publishers and comes as Google faces scrutiny over the impact of its AI features on web traffic. Digiday first reported on the pilot program, which began less than a year ago. As part of the test, Google is reportedly paying participating publishers for how much their content contributed to AI Overviews and AI Mode in Search, as well as its Gemini chatbot. One publisher that joined the program when it first started earned over $1 milli … Read the full story at The Verge.

Labor & Workforce

Get Labor & Workforce signals in your inbox

Deploy Autonomous AI Capabilities & Skills Runtimes

Related desks